Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000229747 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bendamustine in multiple myeloma.
Eur J Haematol
November 2015
Haematology Unit, Department of Onco-Haematology, A.O. of Cosenza, Cosenza, Italy.
The advent of high-dose melphalan with autologous stem-cell transplantation (ASCT), the availability of novel agents such as thalidomide, lenalidomide (immunomodulatory drugs or IMiDs) and bortezomib (proteasome inhibitor) and improvements in supportive care have allowed to increase overall survival in multiple myeloma (MM) patients; nevertheless, MM remains an incurable pathology. For this reason, newer agents are required for continued disease control. Bendamustine is an old drug rediscovered in the last decade.
View Article and Find Full Text PDFBendamustine: new perspective for an old drug in lymphoproliferative disorders.
Expert Rev Hematol
April 2010
Department of Oncology/Haematology, Division of Haematology, Niguarda Ca'Granda Hospital, Piazza Ospedale Maggiore 3, Milan, Italy.
Bendamustine is an old bifunctional alkylating agent that also has potential antimetabolite properties, and only partial cross-resistance with other alkylators. Although it was synthesized in 1963 only few validated study results exist from this early period. More recently, its peculiar mechanism of action has reawakened interest in this drug that has been extensively studied in indolent non-Hodgkin lymphoma (NHL) and in chronic lymphocytic leukemia (CLL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!